Serum BAFF levels and skin mRNA expression in patients with Behçet's disease

Clinical and Experimental Rheumatology

Volumn 26, Issue 4 SUPPL. 50, 2008, Pages

  Hamzaoui, Kamel ^a   Houman, H ^b   Dhifallah, I Ben ^a   Kamoun, M ^a   Hamzaoui, A ^a,c  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

^b LA RABTA HOSPITAL   (Tunisia)

^c ABDERRAHMAN MAMI HOSPITAL   (Tunisia)

Author keywords

B cell activating factor of the TNF family (BAFF); Beh et's disease; Inflammation; Skin lesions

Indexed keywords

B CELL ACTIVATING FACTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; STEROID;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BEHCET DISEASE; CELL SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOGLOBULIN PRODUCTION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SKIN BIOPSY; SKIN DISEASE; SKIN MANIFESTATION; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; VASCULITIS;

ADULT; B-CELL ACTIVATING FACTOR; BEHCET SYNDROME; CASE-CONTROL STUDIES; ERYTHEMA NODOSUM; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER;

EID: 55049130504     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. YAZICI H, YURDAKUL S, HAMURYUDAN et al.: Behçet's syndrome. In: HOCHBERG MC, SILMAN JA, SMOLEN JS, WEINBLATT ME and WEISMAN MH (Eds.): Rheumatology, London, Mosby, 2003: 1665-9.
2. HAMZAOUI A, HAMZAOUI K: Manifestations thoraciques des maladies de Behçet et de Takayasu. Rev Mal Respir 2005; 22: 999-1019.
3. KOC Y, GULLU I, AKPEK G et al.: Vascular involvement in Behçet's disease. J Rheumatol 1992; 19: 402-10.
4. ONDER M, GURER MA: The multiple faces of Behçet's disease and its etiological factors. J Eur Acad Dermatol Venereol 2001; 15: 126-36.
5. HAMZAOUI K, HAMZAOUI A, GUEMIRA F et al.: Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-10.
6. MEGE JL, DILSEN N, SANGUEDOLCE V et al.: Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL)-6, IL-8 and increased neutrophil superoxide generation in Behçet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol 1993; 20: 1544-9.
7. SARUHAN-DIRESKENELI G., YENTUR SP, AKMAN-DEMIR G et al.: Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 2003; 145: 127-34.
8. RAJENDRAM R, RAO NA: Molecular mechanisms in Behçet's disease. Br J Ophthalmol 2003; 87: 1199-200.
9. SUGI-IKAI N, NAKAZAWA M, NAKAMURA S, OHNO S, MINAMI M: Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease. Invest Ophthalmol Vis Sci 1998; 39: 996-1004.
10. OZTAS M O, ONDER M, GURER MA et al.: Serum interleukin 18 and tumour necrosis factor-α levels are increased in Behçet's disease. Clin Exp Dermatol 2005; 30: 61-3.
11. KAMOUN M, CHELBI H. HOUMAN MH, LACHEB J, HAMZAOUI K: Tumor necrosis factor gene polymorphisms in Tunisian patients with Behçet's disease. Hum Immunol 2007; 68: 201-5.
12. TURAN B, GALLATI H, ERDI H, GURLER A, MICHEL BA, VILLIGER PM: Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behçet's disease: Soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997; 24: 128-32.
13. GUL A, ESIN S, DILSEN N, KONICE M, WIGZELL H, BIBERFELD P: Immunohistology of skin pathergy reaction in Behçet's disease. Br J Dermatol 1995; 132: 901-7.
14. MUMCU G, ERGUN T. ELBIR Y et al.: Clinical and immunological effects of azithromycin in Behçet's disease. J Oral Pathol Med 2005; 34: 13-6.
15. SCHNEIDER P, MACKAY F, STEINER et al.: BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999; 189: 1747-56.
16. MOORE PA, BELVEDERE O, ORR A et al.: BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-3.
17. SHU HB, HU WH, JOHNSON H: TALL-1 is a novel member of the TNF family that is down-regulated by mitogens. J Leukoc Biol 1999; 65: 680-3.
18. MUKHOPADHYAY A, NI J, ZHAI Y, YU GL, AGGARWAL BB: Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999; 274: 15978-81.
19. TRIBOULEY C, WALLROTH M, CHAN V et al.: Characterization of a new member of the TNF family expressed on antigen-presenting cells. Biol Chem 1999; 380: 1443-7.
20. THOMPSON JS, BIXLER SA, QIAN F et al.: BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 2001; 293: 2108-11.
21. THOMPSON JS, SCHNEIDER P, KALLED SL et al.: BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med 2000; 192: 129-35.
22. VON BULOW GU, BRAM RJ: NF-AT activation induced by a CAML-interacting member of the tumor necrosis factor receptor superfamily. Science 1997; 278: 138-41.
23. DILLON SR, GROSSNJA, ANSELL SM, NOVAK AJ: An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 2006; 5: 235-46.
24. SUTHERLAND AP, NG LG, FLETCHER CA et al.: BAFF augments certain Th1-associated inflammatory responses. J Immunol 2005; 174: 5537-44.
25. MIGITA K, ABIRU S, YUMI MAEDA Y et al.: Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007; 68: 586-91.
26. INTERNATIONAL STUDY GROUP FOR BEHÇET'S DISEASE: Criteria for the diagnosis of Behçet's disease. Lancet 1990; 335: 1078-80.
27. LAWTON G, BHAKTA BB, CHAMBERLAIN A, TENANT A: The Behçet's disease activity index. Rheumatology 2004; 43: 73-8.
28. TAN EM, COHEN AS, FRIES JF et al.: The 1982 revised criteria for the classification of systemic Jupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
29. POSER CM, PATY DW, SCHEINBERG L et al.: New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
30. DIRI E, MAT C, HAMURYUDAN V, YURDAKUL S, HIZLI N, YAZICI H: Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: A controlled and masked study. Ann Rheum Dis 2001; 60: 1074-6.
31. SATO S, HASEGAWA M, FUJIMOTO M, TEDDER TF, TAKEHARA K: Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000; 165: 6635-43.
32. BLOCH G, TOMA DP, ROBINSON GE: Behavioral rhythmicity, age, division of labor and period expression in the honey bee brain. J Biol Rhythms 2001; 16: 444-56.
33. TOUBIAE, SHOENFELD Y: BLyS/BAFF: a potential target in the treatment of active SLE. IMAJ 2004; 6: 99-102.
34. MATSUSHITA T, HASEGAWA M, YANABA K et al.: Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006; 54: 192-201.
35. THANGARAJH M, MASTERMAN T, HELGELAND L et al.: The thymus is a source of B-cell-survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol 2006; 178: 161-6.
36. THANGARAJH M, KISISWA L, PIRSKANEN R, HILLERT J: The expression of BAFF-binding receptors is not altered in multiple sclerosis or myasthema gravis. Scand J Immunol 2007; 65: 461-6.
37. STOHL W, METYAS S, TAN SM et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-86.
38. SUZUKI N, NARA K, SUZUKI T: Skewed Th1 responses caused by excessive expression of Txk, a member of the Tec family of tyrosine kinases, in patients with Behçet's disease. Clin Med Res 2006; 4: 147-51.
39. NARDELLI B, BELVEDERE O, ROSCHKE V et al.: Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
40. EKSIOGLU-DEMIRALP E, KIBAROGLU A, DIRESKENELI H et al.: Phenotypic characteristics of B cells in Behçet's disease: Increased activity in B cell subsets. J Rheumatol 1999; 26: 826-32.
41. SUZUKI N, SAKANE T, UEDA Y, TSUNEMATSU T: Abnormal B cell function in patients with Behçet's disease. Arthritis Rheum 1986; 29: 212-9.
42. DIRESKENELI H: Autoimmunity vs autoinflammation in Behçet's disease: Do we over-simplify a complex disorder? Rheumatology (Oxford) 2006; 45: 1461-5.
43. BARIS YS, YILDIZ L, SENTÜRK N, KANDEMIR B: Fas (CD95) and bcl-2 expression in active lesions of Behçet's disease. JEADC 2005; 19: 569-72.
44. MELIKOGLU M, UYSAL S, KRUEGER JG et al.: Characterization of the divergent wound-healing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol 2006; 177: 6415-21.
45. FUJIMOTO M, FUJIMOTO Y, POE JC et al.: CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000; 13: 47-57.
46. HAMZAOUI K, KAHAN A, HAMZA M, AYED K: Suppressive T cell function of Epstein-Barr virus-induced B cell activation in active Behçet's disease. Clin Exp Rheumatol 1991; 9: 131-5.
47. DUNCAN MR, BERMAN B: Stimulation of collagen and glycosaminoglycan production in cultured human adult dermal fibroblasts by recombinant human interleukin 6. J Invest Dermatol 1991; 97: 686-92.
48. HASE H, KANNO Y, KOJIMA M et al.: BAFF/BLyS can potentiate B-cell selection with the B-cell co-receptor complex. Blood 2004; 103: 2257-65.
49. STOHL W: A therapeutic role for BLyS antagonists. Lupus 2004: 13: 317-22.
50. KAYAGAKI N, YAN M, SESHASAYEE D et al.: BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002: 17: 515-24.
51. BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of Lympho-Stat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003: 48: 3253-65.
52. GROSS JA, JOHNSTON J, MUDRI S et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000: 404: 995-9.